FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's announcement Aug. 24 that it is reviewing adverse event reports of liver injury related to orlistat - the active ingredient in GlaxoSmithKline's weight-loss product alli could threaten the drug's already slipping sales.